PBLS
Parabilis Medicines, Inc.
Set alert
- YTD
- -10.38%
- 1 year
- -10.38%
- Open
- 28.59
- Prev close
- 28.70
- Mkt cap
- 3.50B
- Vol
- 813.97K
- Avg vol
- 886.16K
- EPS
- -9.51
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 27.48
- High
- 28.74
- Forward P/E
- -12.95
- Beta
- 0.00
- Short ratio
- 7.03
- Inst. own
- 82.48%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 12, 2026
- 50-d avg
- 33.18
- 200-d avg
- 32.26
- 1y target
- 41.40
Key statistics
- Market cap
- 3.50B
- Enterprise value
- 2.47B
- Trailing P/E
- 0.00
- Forward P/E
- -12.95
- PEG ratio
- 0.00
- Price / sales
- 23638.25
- Price / book
- 3.34
- EPS (TTM)
- -9.51
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 148.00K
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 1.12B
- Total debt
- 47.51M
- Return on equity
- 0.00%
- Shares outstanding
- 121.95M
- Short % of float
- 7.59%
- 50-day average
- 33.18
- 200-day average
- 32.26
Analyst view
Consensus: strong buy
- Target (low)
- 40.00
- Target (mean)
- 41.40
- Target (high)
- 45.00
- Strong buy0
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 12, 2026
Expected Nov 12, 2026. Consensus EPS estimate -0.38.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2026 | Sep 30, 2026 | -0.40 | — | — | — |
| Aug 13, 2026 | Jun 30, 2026 | -0.165 | -2.32 | -2.15 | -1,306.06% |
| May 19, 2026 | Mar 31, 2026 | — | -0.72 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 22, 2026 | HC Wainwright & Co. | init | — | Buy |
| Jul 6, 2026 | Guggenheim | init | — | Buy |
| Jul 6, 2026 | Leerink Partners | init | — | Outperform |
| Jul 6, 2026 | B of A Securities | init | — | Buy |
About Parabilis Medicines, Inc.
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- parabilismed.com
News
- Parabilis Medicines: Bullish On Zolucatetide's Broad Oncology Potential
- Parabilis Medicines, Inc. (PBLS) Discusses Updated Zolucatetide Data in Desmoid Tumors and Phase III Path Transcript
- Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027
- Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors
- HC Wainwright & Co. Initiates Coverage On Parabilis Medicines with Buy Rating, Announces Price Target of $40
- Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday
- Parabilis Medicines To Present Updated Clinical Data For Zolucatetide In Patients With Desmoid Tumors At ESMO Congress 2026
- Parabilis Medicines Initiates Dose-Ranging Clinical Cohort Evaluating Zolucatetide In Patients With Familial Adenomatous Polyposis As Part Of Ongoing Phase 1/2 Clinical Trial
Your note
Sign in to keep a note on PBLS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BORISY ALEXIS | Director | Conversion of Exercise of derivative security | Jun 10, 2026 | 105,414 |
| FITZGERALD EDWARD M | Director | Conversion of Exercise of derivative security | Jun 10, 2026 | 14,688 |
| FLYNN JAMES E | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jun 10, 2026 | 0 |
| LEVY GUY B | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 10, 2026 | 0 |
| RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jul 21, 2026 | 0 |
| SEBULSKY ALAN M | Director | Purchase | Jun 14, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 23.73% | 28,933,371 | 819.39M | Jun 29, 2026 |
| FMR, LLC | 8.44% | 10,292,735 | 291.49M | Jun 29, 2026 |
| Arch Venture Management, Llc | 5.26% | 6,412,780 | 181.61M | Jun 29, 2026 |
| venBio Partners LLC | 4.32% | 5,266,697 | 149.15M | Jun 29, 2026 |
| Alphabet Inc. | 4.03% | 4,919,498 | 139.32M | Jun 29, 2026 |
| Nextech Invest, Ltd. | 3.82% | 4,663,176 | 132.06M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 0.92% | 1,121,000 | 31.75M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 0.84% | 1,027,321 | 29.09M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 0.66% | 807,764 | 22.88M | Jun 29, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.40% | 486,669 | 13.78M | Jun 29, 2026 |
| JPMorgan Trust II-JPMorgan Small Cap Growth Fund | 0.39% | 480,209 | 13.60M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 0.39% | 478,759 | 13.56M | Aug 30, 2026 |